Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Nature

Volumn 464, Issue 7291, 2010, Pages 1067-1070

  Davis, Mark E ^a   Zuckerman, Jonathan E ^a   Choi, Chung Hang J ^a   Seligson, David ^b   Tolcher, Anthony ^c   Alabi, Christopher A ^a,f   Yen, Yun ^d   Heidel, Jeremy D ^e   Ribas, Antoni ^b  

^a California Institute of Technology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c South Texas Accelerated Research Therapeutics   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e Calando Pharmaceuticals   (United States)

^f Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; COMPLEMENTARY DNA; CYCLODEXTRIN; DOUBLE STRANDED RNA; INTERFERON; MACROGOL; MESSENGER RNA; NANOPARTICLE; POLYMER; PROTEIN; PROTEIN RRM2; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG;

BIOCHEMISTRY; DISEASE TREATMENT; ENZYME ACTIVITY; HOMINID; NANOTECHNOLOGY; NEMATODE; PROTEIN; RNA; TUMOR;

ARTICLE; CAENORHABDITIS ELEGANS; CANCER GENE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG MECHANISM; GENE DELIVERY SYSTEM; GENE REPRESSION; GENE TARGETING; HUMAN; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SOLID TUMOR; SUBRETINAL NEOVASCULARIZATION; TUMOR BIOPSY;

BIOPSY; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INJECTIONS, INTRAVENOUS; MELANOMA; NANOPARTICLES; RECEPTORS, TRANSFERRIN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

CAENORHABDITIS ELEGANS; MAMMALIA;

EID: 77951132901     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature08956     Document Type: Article

References (25)

1. Bumcrot, D., Manoharan, M., Koteliansky, V. & Sah, D. W. Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711-719 (2006).
2. Castanotto, D. & Rossi, J. J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426-433 (2009).
3. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). (Pubitemid 28099681)
4. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
5. McCaffrey, A. P. et al. RNA interference in adult mice. Nature 418, 38-39 (2002).
6. Lewis, D. L., Hagstrom, J. E., Loomis, A. G., Wolff, J. A. & Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nature Genet. 32, 107-108 (2002).
7. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 9, 347-351 (2003).
8. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
9. DeVincenzo, J. et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77, 225-231 (2008).
10. Leachman, S. A. et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 18, 442-446 (2010).
11. Alvarez, R. et al. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent anti-viral strategy. Antimicrob. Agents Chemother. 53, 3952-3962 (2009).
12. Kleinman, M. E. et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
13. Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668 (2009).
14. Heidel, J. D. et al. Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 13, 2207-2215 (2007).
15. Gatter, K. C., Brown, G., Trowbridge, I. S., Wollston, R. E. & Mason, D. Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539-545 (1983).
16. Cerqueira, N. M. F. S. A., Pereira, S., Fernandes, P. A. & Ramos, M. J. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumor therapy. Curr. Med. Chem. 12, 1283-1294 (2005).
17. Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715-5721 (2007).
18. Koldehoff, M., Steckel, N. K., Beelen, D. W. & Elmaagacli, A. H. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin. Exp. Med. 7, 47-55 (2007).
19. Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104, 15549-15554 (2007).
20. Schluep, T. et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc. Natl Acad. Sci. USA 106, 11394-11399 (2009).
21. Riehl, R., Schartl, M. & Kollinger, G. Comparative studies on the ultrastructure of malignant melanoma in fish and human by freeze-etching and transmission electron microscropy. J. Cancer Res. Clin. Oncol. 107, 21-31 (1984).
22. Juhasz, A., Vassilakos, A., Chew, H. K., Gandara, D. & Yen, Y. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol. Rep. 15, 1299-1304 (2006).
23. Bartlett, D. W. & Davis, M. E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975-985 (2008).
24. McClarty, G. A., Chan, A. K., Engstrom, Y., Wright, J. A. & Thelander, L. Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line. Biochemistry 26, 8004-8011 (1987).
25. Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322-333 (2006)